Press Releases

A phase 1/2 clinical trial for patients with metastatic kidney cancer demonstrated that a novel two-agent treatment regimen developed at Roswell Park more than doubled progression-free survival compared with single-agent treatment. Saby George, MD, FACP, presented the findings at the European Society for Medical Oncology (ESMO) Congress in Barcelona, Spain.

Roswell Park is pleased to be recognized again on Forbes’ Best Employers by State listing, ranked in the top 10 among New York State employers. Roswell Park is the only healthcare organization in Western New York to make this year’s list, and one of only two health employers in the top 10 for New York.

Hyundai Hope On Wheels awarded a $100,000 Hyundai Impact Award Grant to Roswell Park Comprehensive Cancer Center to continue its long-standing fight against pediatric cancer. The Hyundai Impact Award was presented to Kanwal Mallhi, MD.

A new collaboration will see Roswell Park Comprehensive Cancer Center partnering with the University of New Mexico (UNM), supported by a grant from the Bristol Myers Squibb Foundation, to address health disparities for the Pueblo Nations of New Mexico.

New research led by Roswell Park’s Brian Betts, MD, shows that adding a JAK inhibitor to standard treatment did not improve GvHD prevention for patients with hematologic cancers. Further research is warranted to determine whether this strategy might benefit patients who experience the chronic, more widely systemic form of GVHD.

New research led by Roswell Park experts in health behavior suggests that daily e-cigarette use may help some people to quit using combustible cigarettes.

Roswell Park made its debut on the Forbes list of America’s Best Employers for Women 2024, ranking in the top one-quarter among the 600 organizations included. Roswell Park is one of only three cancer centers nationally to be recognized with this prestigious distinction, which is presented by Forbes and Statista Inc.

Roswell Park has appointed five new leaders overseeing various aspects of patient care and supportive services. One is new to Roswell Park, while three are clinical team members promoted to new roles.

The U.S. Food and Drug Administration (FDA) has expanded orphan drug designation for SurVaxM, a brain cancer immunotherapy born in the labs of Roswell Park Comprehensive Cancer Center. The supplemental designation awarded to MimiVax Inc. now applies to SurVaxM as treatment for not just adult glioblastoma but a broader category of cancerous brain tumors: any malignant glioma in children or adults.